# Sumitomo Chemical India share price today (Sumitomo Chemical India Ltd, NSE: SUMICHEM)

> Sumitomo Chemical India share price today: ₹313.90 at the NSE close on 3 November 2026, down 37.5% in a year. Sumitomo Chemical India (NSE: SUMICHEM) is worth ₹15,673 crore, trades at a P/E of 28.5 and has closed between ₹313.90 and ₹564.95 over the past 52 weeks. > Sumitomo Chemical India Ltd's P/E is near the low end of its own history, higher than only 0% of past readings, and its quarterly results are still getting worse. SUMICHEM · Pesticides/Agrochemicals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from the last 12 quarters
- Price: ₹313.90 (−37.5% in a year)
- P/E: 28.5× (lower than 100% of the last 6.7 years)
- Revenue (Sep 2026): ₹907 Cr (−2.5% on a year ago)
- Profit (Sep 2026): ₹157 Cr (−11.8% on a year ago)
- Operating margin: 20.0% (−3.0 points on a year ago)
- ROCE: 22%, FY26
- ROIC: 17.5%, against a 12.0% cost of capital: +5.5 points

The main question: yearly earnings per share moved +7.4% while the share price moved −37.5%. ## What is the Sumitomo Chemical India share price today? Sumitomo Chemical India Ltd's share price was ₹313.90 at the close on 3 November 2026. It has been falling for 2 weeks. That is 32.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹314 and ₹565, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 6 weeks running. Over the last 6.8 years the share price moved +36% while the NIFTY 500 moved +120%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Sumitomo Chemical India this quarter? Three changes stood out: indian funds and insurers (DIIs) raised their stake for 7 quarters in a row, profit fell in the September 2026 quarter and operating margin down 3 points on a year earlier. 1. Indian funds and insurers (DIIs) raised their stake for 7 quarters in a row From 7% to 9.7% of the company by the September 2026 quarter. 2. Profit fell in the September 2026 quarter Profit was ₹157 crore, -11.8% on a year earlier (₹178 crore), after 2 quarters of growth. Next results: check that stock levels fall as the company's fixes take hold. From the earnings call on 27 Oct 2026. 3. Operating margin down 3 points on a year earlier 20% in the September 2026 quarter, from 23%. Next results: check whether margins return to the normal historical range. From the earnings call on 27 Oct 2026. ## What are Sumitomo Chemical India's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Sumitomo Chemical India reported revenue of ₹907 crore, down 2.5% from ₹930 crore a year earlier, and a profit of ₹157 crore, down 11.8% from ₹178 crore. ### Sumitomo Chemical India results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹907 crore | ₹930 crore | −2.5% |
| Profit | ₹157 crore | ₹178 crore | −11.8% |
| Earnings per share | ₹3.15 | ₹3.56 | −11.5% |
| Operating margin | 20.0% | 23.0% | −3.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Sumitomo Chemical India's management discussed these results on a call held on 27 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Sumitomo Chemical India share price history? Sumitomo Chemical India closed at ₹313.90 on 3 November 2026, down 37.5% from ₹502.20 a year earlier (31 October 2025) and down 19.5% over five years. Its highest weekly close since February 2020 was ₹630.65 on 1 August 2025. ### Sumitomo Chemical India share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹360.60 | −13.0% |
| 1 month ago · 1 Oct 2026 | ₹417.60 | −24.8% |
| 6 months ago · 30 Apr 2026 | ₹419.15 | −25.1% |
| 1 year ago · 31 Oct 2025 | ₹502.20 | −37.5% |
| 3 years ago · 3 Nov 2023 | ₹372.20 | −15.7% |
| 5 years ago · 4 Nov 2021 | ₹389.75 | −19.5% |
| Earliest weekly close in our records · 1 Feb 2020 | ₹231.05 | +35.9% |
| Highest weekly close since February 2020 · 1 Aug 2025 | ₹630.65 | −50.2% |
| Lowest weekly close since February 2020 · 27 Mar 2020 | ₹168.50 | +86.3% |
| 52-week high (weekly close) · 14 Aug 2026 | ₹564.95 | −44.4% |
| 52-week low (weekly close) · 3 Nov 2026 | ₹313.90 | 0.0% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (357 weekly closes from 1 February 2020 to 3 November 2026.)

## What is the latest news on Sumitomo Chemical India? 3 Nov 2026: Sumitomo Chemical India closed at ₹313.90, down 13.0% on the week and down 24.8% on the month. 27 Oct 2026: Sumitomo Chemical India held its results call for July to September 2026. Management guided: H2 sales planned above last year where markets allow, while parent-company exports remain soft; broader normalization expected next year. ### Earlier

- Results for July to September 2026: Revenue down 2.5% and profit down 11.8% on a year earlier. - Our read, 22 Aug 2026: The latest quarter combined higher revenue, profit and operating margin with no flagged one-off in the results ledger.,New products, herbicides and price actions are the named demand and margin levers.,The case breaks if pricing and mix cannot defend margins through the monsoon-sensitive season. - 17 Jul 2026: ex-date for a dividend of ₹1.30 a share. ### Our read of the business

The latest quarter combined higher revenue, profit and operating margin with no flagged one-off in the results ledger.,New products, herbicides and price actions are the named demand and margin levers.,The case breaks if pricing and mix cannot defend margins through the monsoon-sensitive season. April to June 2026: Revenue and reported profit improved against the comparable quarter, with operating margin higher. (Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What dividend does Sumitomo Chemical India pay? Sumitomo Chemical India paid ₹1.30 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.41% at the ₹313.90 close on 3 November 2026. The last was a dividend of ₹1.30 a share, ex-date 17 July 2026. ### Sumitomo Chemical India dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 17 Jul 2026 | ₹1.30 | Dividend | same day |
| 25 Jul 2025 | ₹1.20 | Dividend | same day |
| 19 Jul 2024 | ₹0.90 | Dividend | same day |
| 14 Feb 2024 | ₹5 | Special | same day |
| 21 Jul 2023 | ₹1.20 | Dividend | same day |
| 21 Jul 2022 | ₹1 | Dividend | 22 Jul 2022 |
| 22 Jul 2021 | ₹0.80 | Dividend | 23 Jul 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Sumitomo Chemical India Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 8 of its last 9 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Sumitomo Chemical India management say on the latest results call? On the call for July to September 2026, held on 27 October 2026, Sumitomo Chemical India's management guided: H2 sales planned above last year where markets allow, while parent-company exports remain soft; broader normalization expected next year. > “Our goal for H2 is to grow over last year's sales where the market allows, while protecting profitability.”
> Dr. Suresh Ramachandran, on the call for July to September 2026

### What management guided

- H2 margins expected in the normal historical range, inventory expected to normalize, and sales returns not expected to affect H2. - Dahej ₹150 crore herbicide-intermediate project: commercial production July to September 2028 (July-October 2028), payback under 5 years and company-level margins. - Tarapur additions: ₹10 crore each across two projects, adding 3-4 products; first part within FY27, second by FY28-end. - Top Grain full-country rollout planned next season, including wheat in February-March; 1-2 specialty molecules tested annually, with commercialization after 4-5 years; innovation index goal 9-10%. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/5712/Conference Call/CC-Oct26.pdf). (From the call for July to September 2026, 27 October 2026.)

## What is the future of Sumitomo Chemical India? What is changing in the business? What is changing at Sumitomo Chemical India, from the latest results and calls: specialty and herbicide mix, calibrated price pass-through and innovation access from parent. - Specialty and herbicide mix. Specialty products and herbicides are the principal revenue-mix levers. ✓ fact
- Calibrated price pass-through. Successive product-specific price actions are intended to protect margins from input and freight inflation. ✓ fact
- Innovation access from parent. India's higher testing role can shorten the path from parent technology to local launches. ✓ fact
- Self-funded backward integration. Cash generation can fund Dahej and Tarapur projects without a financing dependency. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What could change the Sumitomo Chemical India story? What are the risks? A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure. ### Each change stops working if

- Specialty and herbicide mix: Specialty launches do not gain repeat demand or channel returns rise. - Calibrated price pass-through: Farmer demand weakens after price increases or competitors discount aggressively. - Innovation access from parent: Testing does not convert into registrations and commercial launches. - Self-funded backward integration: Projects are deferred again or capital spending does not create a cost or supply advantage. ### The main risks

- Monsoon and farm-demand volatility: Kharif demand depends on rainfall timing and distribution. ⚠ estimate
- Input-cost and competitive pass-through: Raw material, packaging, solvent and freight inflation can pressure margin if price actions fail. ⚠ estimate
- Capital spending execution and timeline slippage: Dahej and Tarapur economics arrive later if approvals or construction move again. ⚠ estimate
- Export and logistics disruption: Shipment delays and container constraints can interrupt export conversion. ⚠ estimate

(Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Sumitomo Chemical India's next results? When Sumitomo Chemical India reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Parent-company export shipments should show destocking unwind; compare Japanese flows with third-party demand. - What to check (from the call)
- Parent-company export shipments should show destocking unwind; compare Japanese flows with third-party demand. - Inventory and net working capital should trend down as corrective actions progress. - Track Dahej and Tarapur milestones against their stated production and completion schedules. ## Which stock lists is Sumitomo Chemical India on? Sumitomo Chemical India is on 2 of our India lists: 52 week high & low and Small & mid cap stocks. - [52 week high & low 52-week position: At 52-week low](https://www.sectoralpha.in/52-week-high-stocks-india)
- [Small & mid cap stocks Size rank in India: 416](https://www.sectoralpha.in/small-cap-stocks-india)

## Is Sumitomo Chemical India profitable? Sumitomo Chemical India Ltd earned ₹157 Cr of net profit in the Sep 2026 quarter, −11.8% on the same quarter a year earlier. Full-year FY26 profit was ₹543 Cr. Over 8 years profit has grown 17.9% a year on average. That is 17.3% of the quarter's revenue. The same quarter a year earlier earned ₹178 Cr. For the full year, FY26 profit was ₹543 Cr (+7.3% on the year before). Why profit moved: revenue changed −2.5% on a year earlier and the margin moved −3.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +1.9% and revenue −3.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Sumitomo Chemical India make, and is it growing? Sumitomo Chemical India Ltd reported ₹907 Cr of revenue in the Sep 2026 quarter, −2.5% on the same quarter a year earlier. Over 8 years it has grown 6.8% a year on average. The last full year, FY26, came in at ₹3,238 Cr. The last four reported quarters add to ₹3,222 Cr. Why this happened. Management links margin expansion to specialty mix, with recently launched products becoming a larger part of domestic revenue. Herbicide growth and branded formulations provide evidence that this is a product-mix story rather than only broad pricing. FY26 revenue was ₹3,238 Cr, +2.8% on the year before. Recent pace: the last four quarters grew −3.2% on average, against 6.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −2.6%, against +2.9% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +2.9%, against +7.4% a year (rolling over). ## How much of every ₹100 of sales does Sumitomo Chemical India keep? Sumitomo Chemical India Ltd's operating margin was 20.0% in the Sep 2026 quarter, 3.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 9 years it has been between 11.0% and 21.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −3.0 percentage points on the year while gross margin changed −2.4 points. So the drop came mostly from the gross margin, which means input costs and prices charged. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Sumitomo Chemical India's profit turning into cash? Over the last 3 years, 117% of Sumitomo Chemical India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹446 Cr of operating cash against ₹543 Cr of profit. After ₹79.0 Cr of spending on assets, ₹367 Cr was left over as free cash. Why this happened. The cash record shows free cash generation over the multi-year window and management describes internal cash and retained earnings as the capex funding source. The Capex Inflection Point model applies only after project commissioning and revenue conversion. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 117% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Sumitomo Chemical India's cash go? Sumitomo Chemical India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 163 days in FY26, up from 157 days in FY21. It spent ₹290 Cr on assets over the last 3 years. Customers take 83 days to pay, and stock sits for 166 days on average. At FY26 sales of ₹3,238 Cr, each day of that cycle ties up about ₹8.9 Cr, so roughly ₹1,446 Cr is tied up in the business at any time. FY26: customers took 83 days to pay and stock sat for 166 days, about 5.5 months of sales sitting as stock, for a full cycle of 163 days, longer than FY21's 157. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 166 days. Customers pay about 83 days after that. Suppliers are paid at 86 days. Together that makes the 163-day cycle. Spending on assets: ₹290 Cr over the last 3 years, against ₹194 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹20.0 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Sumitomo Chemical India's P/E ratio, and how does it compare with its own history? Sumitomo Chemical India Ltd's P/E is 28.5×, about the lowest it has ever been. Its usual P/E (the middle reading) is 51.7×, over 6.7 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹11.20. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +7.4% while the price moved −37.5%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −4.2% a year; about +8.3% a year came from earnings growth and about −12.5 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Sumitomo Chemical India business getting better or worse? Sumitomo Chemical India Ltd's business is growing steadily. Profit and EPS growth have stayed positive throughout, and ROCE is steady at 21.3%. This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## What is the Sumitomo Chemical India story, and has it been checked? Sumitomo Chemical India Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: EARLY EXPANSION. Still open: A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure. Our read, 22 August 2026. From the numbers. The operating and price curves indicate early expansion with price below its prior peak. From the price. Price stage 4, week 2, below its 200-day line, relative strength falling. From the research. Where they disagree. The operating and price curves indicate early expansion with price below its prior peak. What is proven. What is not proven yet. A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure. What would change our mind. A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure. The test written in advance. A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure. Measured by: the thesis as written as stated by the next result. The test written in advance. The test written in advance. Monsoon and farm-demand volatility. Measured by: Monsoon and farm-demand volatility Domestic revenue declines year on year during the Kharif quarter. by the next result. What the company does. The latest quarter combined higher revenue, profit and operating margin with no flagged one-off in the results ledger. New products, herbicides and price actions are the named demand and margin levers. The case breaks if pricing and mix cannot defend margins through the monsoon-sensitive season. What the surface reading misses. What the surface reading misses. The surface reading is: Cash generation broadly tracks reported earnings. The research reads it further: The multi-year result is supported by free cash generation, although latest-year conversion is lower because working capital absorbed cash. Lever 2 · Value-added mix: building. Specialty products and herbicides are the principal revenue-mix levers. What proves it keeps working: Specialty and herbicide mix. It stops working if Specialty launches do not gain repeat demand or channel returns rise. Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Sumitomo Chemical India management deliver what it promised? What Sumitomo Chemical India Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Semiconductor Role Has Become Uncertain · 27 October 2026. In Oct 2025 and May 2026, management described SCIL as actively involved in the semiconductor discussions and planned bringing the business into the listed entity. In Oct 2026, management said that no concrete structure or specific role had been defined, materially reducing the certainty around a previously presented strategic growth opportunity without explaining the change. Capital Deployment Commitment Softened · 27 October 2026. The Oct 2025 and May 2026 calls framed Dahej and other capex as the intended destination for a large share of accumulated cash. In Oct 2026, management said cash deployment was a smaller part of the agenda and offered no definitive timeline. Although the announced projects remain on track and management did not state that cash would be returned, the scale and urgency of deployment have materially changed without explanation. Dahej Timeline Is Internally Conflicted · 27 October 2026. The Oct 2025 call pointed to revenue generation sometime in calendar year 2028 after an implementation period of 18 months to 2 years. Dahej Project Timeline Slippage · 28 October 2025. The timeline for the strategic Dahej greenfield project has been pushed back without explanation. In the May 2025 call, management stated initial manufacturing would deliver products starting in 2027. However, in the October 2025 call, the first revenue from the project is now expected in 2028, representing a delay of at least one year for this key growth initiative. Earlier call (May 2025): “we want to start manufacturing certain products to deliver between”. Later call (Oct 2025): “we expect that during this current financial year some of these project should go and get approved... with implementation timelines of 18 months to two years. So maybe sometime in calendar year 2028 we see that that some of these projects should start generating revenues.”

Every quote above is taken word for word from the company’s own earnings calls. ## How much does Sumitomo Chemical India earn on its capital? Sumitomo Chemical India Ltd earned a ROCE of 22% in FY26. That is up from a low of 20% in FY24. Its return on capital used (ROIC) is 5.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 16.8% net margin and 0.72× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 16.8% net margin × 0.72× asset turnover × 1.32× leverage (assets divided by equity) ≈ 16.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 17.5% − 12.0% = +5.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 17.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 23.4%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Sumitomo Chemical India have too much debt? Sumitomo Chemical India Ltd has total debt of ₹56.0 Cr against shareholder equity of ₹3,701 Cr as of Sep 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.02 in FY22 to 0.02 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Sumitomo Chemical India shareholding pattern? Domestic institutions raised their stake in Sumitomo Chemical India Ltd by 2.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 9.7% of the company. Foreign institutions moved −0.6 points over the same period, to 2.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +2.7 points over 8 quarters, to 9.7%; Foreign institutions: −0.6 points over 8 quarters, to 2.9%; Promoters: +0.0 points over 8 quarters, to 75.0%. Why the owners changed: domestic institutions drove it (+2.7 points), with the other side taken by foreign institutions (−0.6 points). They raised their stake step by step. ## How far is Sumitomo Chemical India from balance-sheet trouble? For Sumitomo Chemical India Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sumitomo Chemical India rank in its industry? 41.7 out of 100, rank 20 of 25 in Pesticides/Agrochemicals, with 85% of the evidence available. Sumitomo Chemical India Ltd scores 41.7 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 20. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 8.1 + 18.6 + 7.2 + 7.8 = 41.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sumitomo Chemical India compared with? Sumitomo Chemical India ranks 20 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 41.7 out of 100. 1. [Sharda Cropchem Ltd](https://www.sectoralpha.in/stocks/sharda-cropchem-ltd) SHARDACROP · basing · Most evidence points up · 100% evidence 71.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 17.3% · Profit 42.5% · Operating margin change 2 points · 100% evidence Capital efficiency 19.5/25 · ROCE 30.2% · Operating margin 16% · 100% evidence Valuation 19.2/20 · P/E 9.3× · PEG 0.3 · 100% evidence Relative strength 4.6/20 · Lead over its industry -14.3% · Lead over NIFTY 500 -22.1% · 1 year -23.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28.5 + 19.5 + 19.2 + 4.6 = 71.8 · What this means: Earnings are strong; relative strength in its sector is -14.3% and the one-year return is -23.1%. 2. [Titan Biotech Ltd](https://www.sectoralpha.in/stocks/titan-biotech-ltd) turning · Most evidence points up · 83% evidence 70.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.1/35 · Revenue 31.8% · Profit 38.7% · Operating margin change 2 points · 83% evidence Capital efficiency 20.2/25 · ROCE 22.8% · Operating margin 21% · 95% evidence Valuation 5.4/20 · P/E 51.8× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 38.3% · Lead over NIFTY 500 25.1% · 1 year 101.5% · 100% evidence · 4 of 12 weeks ahead Exact sum: 28.1 + 20.2 + 5.4 + 16.7 = 70.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Bayer CropScience Ltd](https://www.sectoralpha.in/stocks/bayer-cropscience-ltd) BAYERCROP · quiet · Evidence leans up · 81% evidence 63.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue -2.8% · Profit 23.8% · Operating margin change 2 points · 88% evidence Capital efficiency 19.6/25 · ROCE 29.1% · Operating margin 20% · 100% evidence Valuation 13.4/20 · P/E 20× · PEG 1.28 · 100% evidence Relative strength 8.6/20 · Lead over its industry n/a · Lead over NIFTY 500 -20.8% · 1 year -33.3% · 25% evidence · 0 of 12 weeks ahead Exact sum: 22.3 + 19.6 + 13.4 + 8.6 = 63.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Punjab Chemicals & Crop Protection Ltd](https://www.sectoralpha.in/stocks/punjab-chemicals-crop-protection-ltd) PUNJABCHEM · quiet · Evidence leans up · 81% evidence 63.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 8.2% · Profit 43.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.6/25 · ROCE 18.6% · Operating margin 12% · 100% evidence Valuation 15.9/20 · P/E 17.4× · PEG 0.33 · 100% evidence Relative strength 9.8/20 · Lead over its industry n/a · Lead over NIFTY 500 -9.4% · 1 year -36.4% · 25% evidence · 6 of 12 weeks ahead Exact sum: 24.3 + 13.6 + 15.9 + 9.8 = 63.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Dharmaj Crop Guard Ltd](https://www.sectoralpha.in/stocks/dharmaj-crop-guard-ltd) DHARMAJ · losing its lead · Evidence leans up · 81% evidence 63.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 8.7% · Profit 13.2% · Operating margin change 1 points · 88% evidence Capital efficiency 14.7/25 · ROCE 16.8% · Operating margin 15% · 100% evidence Valuation 17.5/20 · P/E 14.3× · PEG 0.38 · 100% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 4.7% · 1 year -9.9% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.8 + 14.7 + 17.5 + 12.2 = 63.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [India Pesticides Ltd](https://www.sectoralpha.in/stocks/india-pesticides-ltd) IPL · quiet · Evidence leans up · 81% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.6/35 · Revenue 17% · Profit 10.1% · Operating margin change -2 points · 88% evidence Capital efficiency 15.4/25 · ROCE 16.6% · Operating margin 14% · 100% evidence Valuation 18.2/20 · P/E 12× · PEG 0.36 · 100% evidence Relative strength 8.2/20 · Lead over its industry n/a · Lead over NIFTY 500 -23% · 1 year -40.7% · 25% evidence · 0 of 12 weeks ahead Exact sum: 17.6 + 15.4 + 18.2 + 8.2 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Advance Agrolife Ltd](https://www.sectoralpha.in/stocks/advance-agrolife-ltd) ADVANCE · breaking out · Evidence leans up · 64% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.1/35 · Revenue 48.4% · Profit 81.5% · Operating margin change 1 points · 88% evidence Capital efficiency 14.1/25 · ROCE 19.6% · Operating margin 11% · 100% evidence Valuation 10.3/20 · P/E 16.3× · PEG n/a · 15% evidence Relative strength 12.4/20 · Lead over its industry n/a · Lead over NIFTY 500 10.6% · 1 year -8.6% · 25% evidence · 12 of 12 weeks ahead Exact sum: 22.1 + 14.1 + 10.3 + 12.4 = 58.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) DHANUKA · turning · Evidence leans up · 100% evidence 57.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.8/35 · Revenue 0% · Profit 0.7% · Operating margin change 0 points · 100% evidence Capital efficiency 19.6/25 · ROCE 25.9% · Operating margin 23% · 100% evidence Valuation 9.2/20 · P/E 14.4× · PEG 2.27 · 100% evidence Relative strength 17.4/20 · Lead over its industry 7.1% · Lead over NIFTY 500 -2.8% · 1 year -28.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 10.8 + 19.6 + 9.2 + 17.4 = 57 · What this means: Relative strength against the index is -2.8%, and revenue and profit growth are weak. 9. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) JUBLINGREA · quiet · Evidence leans up · 93% evidence 54.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.0/35 · Revenue 15.4% · Profit 21.9% · Operating margin change 3 points · 100% evidence Capital efficiency 13.6/25 · ROCE 11.4% · Operating margin 15% · 100% evidence Valuation 6.7/20 · P/E 24.7× · PEG 2.26 · 65% evidence Relative strength 8.4/20 · Lead over its industry -2.6% · Lead over NIFTY 500 -11.7% · 1 year -19.1% · 100% evidence · 3 of 12 weeks ahead Exact sum: 26 + 13.6 + 6.7 + 8.4 = 54.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) MOL · breaking out · Evidence leans up · 64% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue -7.8% · Profit 100% · Operating margin change 7 points · 88% evidence Capital efficiency 9.5/25 · ROCE 6.7% · Operating margin 18% · 100% evidence Valuation 9.6/20 · P/E 20.8× · PEG n/a · 15% evidence Relative strength 11.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.5% · 1 year -35% · 25% evidence · 11 of 12 weeks ahead Exact sum: 22 + 9.5 + 9.6 + 11 = 52.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [GSP Crop Science Ltd](https://www.sectoralpha.in/stocks/gsp-crop-science-ltd) GSPCROP · quiet · Too little evidence to rank firmly · 59% evidence 51.0 out of 100 Growth Capital Valuation Relative
12. [Epigral Ltd](https://www.sectoralpha.in/stocks/epigral-ltd) EPIGRAL · quiet · Evidence leans down · 81% evidence 49.6 out of 100 Growth Capital Valuation Relative
13. [Rallis India Ltd](https://www.sectoralpha.in/stocks/rallis-india-ltd) RALLIS · quiet · Evidence leans down · 85% evidence 48.4 out of 100 Growth Capital Valuation Relative
14. [Bharat Rasayan Ltd](https://www.sectoralpha.in/stocks/bharat-rasayan-ltd) BHARATRAS · quiet · Evidence leans down · 96% evidence 45.3 out of 100 Growth Capital Valuation Relative
15. [Bhagiradha Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/bhagiradha-chemicals-industries-ltd) BHAGCHEM · quiet · Evidence leans down · 96% evidence 44.7 out of 100 Growth Capital Valuation Relative
16. [Shivalik Rasayan Ltd](https://www.sectoralpha.in/stocks/shivalik-rasayan-ltd) SHIVALIK · Evidence leans down · 63% evidence 43.9 out of 100 Growth Capital Valuation Relative
17. [Excel Industries Ltd](https://www.sectoralpha.in/stocks/excel-industries-ltd) EXCELINDUS · quiet · Evidence leans down · 64% evidence 42.7 out of 100 Growth Capital Valuation Relative
18. [NACL Industries Ltd](https://www.sectoralpha.in/stocks/nacl-industries-ltd) NACLIND · basing · Evidence leans down · 96% evidence 42.0 out of 100 Growth Capital Valuation Relative
19. [Best Agrolife Ltd](https://www.sectoralpha.in/stocks/best-agrolife-ltd) BESTAGRO · quiet · Evidence leans down · 90% evidence 42.0 out of 100 Growth Capital Valuation Relative
20. Sumitomo Chemical India Ltd this page SUMICHEM · quiet · Evidence leans down · 85% evidence 41.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.1/35 · Revenue -2.6% · Profit 3% · Operating margin change -3 points · 100% evidence Capital efficiency 18.6/25 · ROCE 22.1% · Operating margin 20% · 100% evidence Valuation 7.2/20 · P/E 28.6× · PEG 4 · 100% evidence Relative strength 7.8/20 · Lead over its industry n/a · Lead over NIFTY 500 -26.4% · 1 year -37.3% · 25% evidence · 3 of 12 weeks ahead Exact sum: 8.1 + 18.6 + 7.2 + 7.8 = 41.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 21. [UPL Ltd](https://www.sectoralpha.in/stocks/upl-ltd) UPL · basing · Evidence leans down · 71% evidence 41.5 out of 100 Growth Capital Valuation Relative
22. [Insecticides India Ltd](https://www.sectoralpha.in/stocks/insecticides-india-ltd) INSECTICID · quiet · Evidence leans down · 96% evidence 40.5 out of 100 Growth Capital Valuation Relative
23. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) PIIND · quiet · Evidence leans down · 81% evidence 38.3 out of 100 Growth Capital Valuation Relative
24. [Astec Lifesciences Ltd](https://www.sectoralpha.in/stocks/astec-lifesciences-ltd) ASTEC · quiet · Most evidence points down · 71% evidence 32.7 out of 100 Growth Capital Valuation Relative
25. [Heranba Industries Ltd](https://www.sectoralpha.in/stocks/heranba-industries-ltd) HERANBA · quiet · Most evidence points down · 76% evidence 29.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pesticides/Agrochemicals](https://www.sectoralpha.in/sectors/pesticides-agrochemicals), all 25 compared on one page. ## Which companies are close to Sumitomo Chemical India in size? Sumitomo Chemical India is the 3rd largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: UPL and P I Industries. Just below it: Bayer CropScience, Jubilant Ingrevia, Sharda Cropchem and Dhanuka Agritech. ### Pesticides/Agrochemicals companies close in size

1. [UPL Ltd](https://www.sectoralpha.in/stocks/upl-ltd) ₹43,322 crore
2. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) ₹31,861 crore
3. Sumitomo Chemical India Ltd ₹15,728 crore
4. [Bayer CropScience Ltd](https://www.sectoralpha.in/stocks/bayer-cropscience-ltd) ₹14,636 crore
5. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) ₹8,894 crore
6. [Sharda Cropchem Ltd](https://www.sectoralpha.in/stocks/sharda-cropchem-ltd) ₹6,000 crore
7. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) ₹4,369 crore

[All 25 Pesticides/Agrochemicals companies, largest first](https://www.sectoralpha.in/sectors/pesticides-agrochemicals#all-companies)

### Companies close in size in other industries

1. [Azad Engineering Ltd](https://www.sectoralpha.in/stocks/azad-engineering-ltd) ₹15,792 crore · Aerospace & Defence - Equipments
2. [JSW Cement Ltd](https://www.sectoralpha.in/stocks/jsw-cement-ltd) ₹15,747 crore · Cement
3. Sumitomo Chemical India Ltd ₹15,728 crore
4. [Emami Ltd](https://www.sectoralpha.in/stocks/emami-ltd) ₹15,703 crore · FMCG - Personal Care
5. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) ₹15,683 crore · Pharma - Formulators

## What else do people ask about Sumitomo Chemical India? ### What is Sumitomo Chemical India's share price today? Sumitomo Chemical India Ltd's share price is ₹313.90, −37.5% over the past year. The whole company is worth ₹15,673 Cr on the market. It is at its lowest price of the past 52 weeks (range ₹314 to ₹565), 32.1% below its 200-day average. The price has been falling for 2 weeks (as of 3 November 2026). ### What were Sumitomo Chemical India's latest quarterly results? Sumitomo Chemical India Ltd reported revenue of ₹907 Cr and net profit of ₹157 Cr for the Sep 2026 quarter. Revenue fell 2.5% and profit fell 11.8% compared with a year earlier. Earnings per share were ₹3.15. The operating margin was 20.0%, 3.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Sumitomo Chemical India's market cap? Sumitomo Chemical India Ltd's market capitalisation is ₹15,673 Cr at a share price of ₹313.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Sumitomo Chemical India performing? Sumitomo Chemical India Ltd's share price has been falling for 2 weeks. In its latest quarter, revenue fell 2.5% and profit fell 11.8% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 6 weeks running (as of 3 November 2026). ### Will Sumitomo Chemical India's share price go up? This page does not forecast Sumitomo Chemical India Ltd's share price. What it shows instead: the share price is ₹313.90, and it has been falling for 2 weeks. Its P/E of 28.5× is higher than 0% of its own last 7 years (as of 3 November 2026). ### Who owns Sumitomo Chemical India? Promoters own 75.0% of Sumitomo Chemical India Ltd, foreign institutions 2.9%, domestic institutions 9.7% and the public 12.4% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 2.7 percentage points over 8 quarters (as of 3 November 2026). ### Does Sumitomo Chemical India have too much debt? No, Sumitomo Chemical India Ltd has little debt: its debt is 0.02× its equity, and its operating profit is 84 times its interest bill. FY26 borrowings were ₹63.0 Cr against equity of ₹3,390 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Sumitomo Chemical India in its business cycle? Sumitomo Chemical India Ltd's FY26 operating margin was 21.0%, against a 9-year range of 11.0% to 21.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 20.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Sumitomo Chemical India story? The main question: yearly earnings per share moved +7.4% while the share price moved −37.5%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Sumitomo Chemical India a stock worth studying right now? What the numbers show: Sumitomo Chemical India Ltd's P/E is near the low end of its own history, higher than only 0% of past readings, and its quarterly results are still getting worse. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Sumitomo Chemical India share price forecast for 2026? What management itself guided: H2 sales planned above last year where markets allow, while parent-company exports remain soft; broader normalization expected next year. What is changing at Sumitomo Chemical India, from the latest results and calls: specialty and herbicide mix, calibrated price pass-through and innovation access from parent. What would change the story: A sustained decline in operating margin below the recent normalized level while volume growth slows would show that pricing and specialty mix are not offsetting cost and demand pressure. ## Lists

- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india
- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india

This is research, not advice. We’re not SEBI-registered.